Time‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens

Polatuzumab vedotin, an antibody‐drug conjugate containing monomethyl auristatin E, was associated with an incidence of grade ≥2 peripheral neuropathy (PN) of 55–72% in patients with indolent non‐Hodgkin lymphoma in a phase II study, when dosed 1.8–2.4 mg/kg every 3 weeks until progression or for a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, D, Gillespie, WR, Girish, S, Agarwal, P, Li, C, Hirata, J, Chu, Y‐W, Kagedal, M, Leon, L, Maiya, V, Jin, JY
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488137/
https://www.ncbi.nlm.nih.gov/pubmed/28544534
http://dx.doi.org/10.1002/psp4.12192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488137/
https://www.ncbi.nlm.nih.gov/pubmed/28544534
http://dx.doi.org/10.1002/psp4.12192

Ejemplares similares